News

Brief points covered in the America Association for Cancer Research (AACR) Virtual Annual Meeting I held on April 27-28th: -Treating BRAF-Positive Melanoma by adding checkpoint inhibitor Tecentriq (atezolizumab) to a combination of two targeted drugs Zelboraf (vemurafenib) and Cotellic (cobimetinib) -PARP Inhibitor (targeted drugs…

May 16th, 2020 A study indicates that children with cancer are not at increased risks of severe cases of COVID-19, and researchers find that Medicaid expansion was associated with reduced cancer deaths. Read more at: https://www.cancertodaymag.org/Pages/cancer-talk/May-15-The-Week-in-Cancer-News.aspx

The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults with advanced bile duct cancer whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene. Full…

The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments. Triple-negative breast cancer is called that because the cancer cells…

Cancer patients are among those at high-risk of serious illness from an infection because their immune systems are often weakened by cancer and its treatments. Although most people who were treated for cancer in the past (especially if it was years ago)…

Researchers have discovered that a fasting-mimicking diet could be more effective at treating some types of cancer when combined with vitamin C. In studies on mice, researchers found that the combination delayed tumor progression in multiple mouse models of colorectal cancer; in…